Mitomycin C-Based Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Colorectal Cancer With Peritoneal Metastasis

Key Points

• Survival improves significantly with mitomycin C-based hyperthermic intraperitoneal chemotherapy in colorectal cancer patients.
• Patients seeing survival benefits showed a 25% increase in overall survival compared to conventional treatments.
• Assessment of the therapy highlights its potential in extending life for those with peritoneal metastasis.
• Further studies are needed to confirm these findings in larger, diverse patient populations.